Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals.
Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals.
复制标题
评估接受HAART治疗和未接受治疗的HIV感染者远端对称性多发性神经病的患病率及其危险因素。
作者：
Jaffer Shiffa Shurie;A. Deribew
背景
在埃塞俄比亚，艾滋病毒/艾滋病患者中的远端感觉性多发性神经病(DSP)的严重程度和危险因素没有得到很好的研究。
客观化
这项研究的目的是确定高活性抗逆转录病毒(HAART)治疗和未治疗的HIV阳性个体中DSP的流行率。
方法
横断面研究于2007年7月至12月在吉马大学专科医院进行。从吉马大学专科医院HIV/AIDS治疗和随访门诊登记的2417名HIV感染者中随机抽取400人。数据收集使用结构化问卷，其中包含艾滋病临床试验小组方案5157的简要周围神经病变筛查工具。我们还查阅了记录，并进行了必要的实验室调查。将数据录入计算机，用SPSS12.0.1统计软件进行统计分析。
结果
在研究参与者中，DSP的总患病率为34.6%(110/318)，其中81/110(73.6%)有症状，29/110(26.4%)无症状。在接受HAART治疗的高度活跃的患者中，DSP的患病率为48%(98/204)，在未接受治疗的患者中，其患病率为10.5%(12/114)。30 mg司他夫定联合HAART方案患者的DSP患病率为43%(52/121)，40 mg司他夫定患者的DSP患病率为74%(40/54)。在齐多夫定联合HAART方案治疗的患者中，20.7%(6/29)的患者发现有DSP。在最近(<；6个月)暴露于HAART和异烟肼(作为标准抗结核药物)的研究参与者中，12人(52%)患有DSP，而在未经治疗的异烟肼(作为标准抗结核药物)暴露的研究参与者中，有2人(25%)发现了DSP。在社会人口学变量中，与年轻参与者相比，年龄较大的参与者患上DSP的可能性是5.3倍。
结论
在我们的研究中，DSP的患病率很高。年龄、大剂量司他夫定/40 mg联合用药是影响DSP的重要危险因素。
BACKGROUND
The magnitude and risk factors of Distal Sensory Polyneuropathy (DSP) among people living with HIV/AIDS is not well studied in Ethiopia.
OBJECTIVE
The objective of this study is to determine the prevalence of DSP among highly active ante-retroviral (HAART)-treated and Untreated HIV-positive individuals.
METHOD
Cross-sectional study was conducted from July-December 2007 in Jimma University Specialized Hospital. From a total of 2417 HIV infected individuals who were registered in the HIV/AIDS treatment and follow-up clinic of Jimma University Specialized Hospital, 400 were selected randomly. Data was collected using structured questionnaires which contained a brief peripheral neuropathy screening tool of AIDS Clinical Trial Group protocol 5157. We also reviewed records and did essential laboratory investigation. Data was entered into computer and analyzed with using SPSS 12.0.1 statistical software.
RESULT
The overall prevalence of DSP among study participant was 34.6% (110/318) of which 81 of 110 (73.6%) were symptomatic and 29 of 110 (26.4%) were asymptomatic. The prevalence of DSP among highly active ante-retroviral HAART-treated was 48% (98/204) and among untreated individuals it was 10.5% (12/114) respectively. The prevalence of DSP among 30 mg stavudine combination HAART regimen users was 43% (52/121) and 74% (40/54) among 40 mg stavudine users. Where as among Zidovudine combination HAART regimen treated individuals, 20.7% (6/29) were found to have DSP. And among recent (<6 months) HAART and isoniazide (as standard anti TB) exposed study participants, 12 (52%) had DSP and among HAART Untreated INH (as standard anti TB) exposed study participants, DSP was found in 2 (25%) of them. Among socio-demographic variables older participants were 5.3 times more likely to develop DSP as compare to young ones.
CONCLUSION
In our study the prevalence of DSP was high. Age and the combined use of high dose stavudine/40 mg were important risk factors for DSP.